ABCF2 positive expression and its relationship with chemotherapy resistance in ovarian carcinoma / 中国生化药物杂志

ABSTRACT

Objective To investigate the positive expression of ATP binding cassette transporter protein F2 (ABCF2) in ovarian cancer tissue and its relationship with chemotherapy resistance.Methods 91 patients with ovarian cancer specimens were selected and 42 cases from the tumor 5cm adjacent tissues as normal controls, ABCF2 expression in each sample was detected by immunohistochemical staining , the relationship between ABCF2 expression and clinicopathological features of patients with ovarian cancer were analyzed .Results The positive expression rate of ABCF2 in ovarian cancer tissue was 68.13%, which was significantly higher than that in normal ovarian tissue (9.52%), and the difference was statistically significant (P<0.05).The positive expression of ABCF2 was not related to the age and organization type of ovarian cancer patients.The positive expression rate of ABCF2 in stage III~IV was 86.54%, which was significantly higher than that of phase I~II (43.59%), the difference was statistically significant (P<0.05). The positive expression rate of ABCF2 in patients with chemotherapy resistance was 88.89%, which was significantly higher than that in patients with chemotherapy sensitivity ( 59.38%) , and the difference was statistically significant ( P<0.05 ) .The results of Logistic regression analysis showed that ABCF2 positive expression was the independent influencing factor of ovarian cancer drug resistance (OR =4.586,95% CI:1.121 ~3.392,P<0.05). Conclusion ABCF2 is highly expressed in ovarian cancer, which may be associated with chemotherapy resistance in patients with ovarian cancer .